Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.85 |
| ▸ | NPC1 | O15118 | 3/20 | 0.85 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.81 |
| ▸ | MAPT | P10636 | 3/20 | 0.81 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.53 |
| ▸ | FEN1 | P39748 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 1/20 | 0.52 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1393818 | 0.92 | L3MBTL1 (0.76) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL5725840 | 0.92 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL10649146 | 0.92 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL13256390 | 0.90 | RAB9A (0.71) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL6202445 | 0.90 | RAB9A (0.71) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL9262872 | 0.90 | RAB9A (0.74) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL10102425 | 0.90 | RAB9A (0.71) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL6199337 | 0.90 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL5318356 | 0.90 | RAB9A (0.71) | RAB9ANPC1L3MBTL1MAPTGSK3B | |
| SCHEMBL6224695 | 0.90 | RAB9A (1.00) | RAB9ANPC1L3MBTL1MAPTGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10662156-B2 | Guanidine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-10662156-B2 | Guanidine derivative and medical use thereof | TORAY INDUSTRIES, INC. (JP) | 2020-05-26 | — | — | US | disclosed |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-08-01 | — | — | US | disclosed |
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2019-08-01 | — | — | US | disclosed |
| EP-3495348-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2019-06-12 | — | — | EP | disclosed |
| EP-3495348-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | Toray Industries, Inc. (JP) | 2019-06-12 | — | — | EP | disclosed |
| WO-2018021520-A1 | GUANIDINE DERIVATIVE AND USE THEREOF FOR MEDICAL PURPOSES | 東レ株式会社 | 2018-02-01 | — | — | WO | disclosed |
| US-9370522-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370522-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-9370522-B2 | Heterocyclic compounds for the inhibition of PASK | BIOENERGENIX, LLC (US) | 2016-06-21 | — | — | US | disclosed |
| US-20050272036-A1 | Ketones | ASTRAZENECA AB (SE) | 2005-12-08 | — | — | US | disclosed |
| EP-1572668-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2005-09-14 | — | — | EP | disclosed |
| EP-1549600-A1 | KETONES | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004060865-A2 | N-(SUBSTITUTED ARYLMETHYL)-4-(DISUBSTITUTED METHYL)PIPERIDINES AND PIPERAZINES | FMC CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004011410-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2004-02-05 | — | — | WO | disclosed |
| US-5478856-A | Styrene derivatives and salts thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1995-12-26 | — | — | US | disclosed |
| EP-0623603-A1 | STYRENE DERIVATIVE AND SALTS THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 1994-11-09 | — | — | EP | disclosed |
| US-5288727-A | Hydrazone compounds, processes for their production, intermediates useful for their production and pesticidal compositions containing them | ISHIHARA SANGYO KAISHA LTD. (JP) | 1994-02-22 | — | — | US | disclosed |
| EP-0500111-A2 | Hydrazone compounds, processes for their production, intermediates useful for their production and pesticidal compositions containing them | ISHIHARA SANGYO KAISHA, LTD. (JP) | 1992-08-26 | — | — | EP | disclosed |
| US-4168315-A | ANTICOAGULANTS | THE UPJOHN COMPANY (US) | 1979-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190233376-A1 | GUANIDINE DERIVATIVE AND MEDICAL USE THEREOF | MALT1, GUCY1A1, GUCY1B1 | RAB9A 945/4885NPC1 1403/4885L3MBTL1 3145/4885 |
| US-10662156-B2 | Guanidine derivative and medical use thereof | MALT1, GUCY1A1, GUCY1B1 | RAB9A 945/4885NPC1 1403/4885L3MBTL1 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.